EMA to finalize trial data disclosure policy in June
This article was originally published in Scrip
Executive Summary
In an attempt to assuage industry's fears about the disclosure of commercially confidential information, the European Medicines Agency is looking at the best way of deleting such information before releasing clinical trial data under its controversial draft policy on proactive disclosure. It says it plans to present the final policy together with an implementation plan to its management board for endorsement at its next meeting in June.